Every S-1 that Amesite Inc (AMST) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-1 covers the registration statement a company files to sell shares publicly, so if you follow AMST and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AMST filings page.
Amesite Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibit-only update. The change is limited to correcting a technical error in the auditor consent filed as Exhibit 23.1, leaving the substantive terms of the registration statement unchanged.
The company discloses estimated offering-related expenses of $60,674.56, including a $674.56 SEC registration fee, $30,000.00 of accounting fees, $25,000.00 of legal fees, and $5,000.00 of miscellaneous costs. Amesite also lists prior unregistered issuances, including employee stock options and shares to consultants under its equity incentive plan.
Amesite Inc. is registering 4,836,245 shares of common stock for resale by existing investors, largely tied to recently issued pre-funded and series warrants plus placement agent warrants. The company itself will not receive proceeds from these resale transactions.
Amesite may receive up to about $5.38 million if all related warrants are exercised for cash. The filing highlights a strategic pivot to AI-powered NurseMagic™ solutions for post-acute healthcare, but also discloses continued operating losses, Nasdaq listing pressures, and substantial doubt about its ability to continue as a going concern without additional financing.
Amesite Inc. is registering 2,777,778 shares of common stock with accompanying warrants, plus related pre-funded warrants and underlying shares, in a primary public offering. The assumed combined price is $1.80 per share and warrant, with estimated net proceeds of about $4.47 million for working capital and general corporate purposes.
Each accompanying warrant has a $1.80 exercise price, is immediately exercisable, and expires five years after issuance. Investors that would exceed 4.99% (or 9.99% at their election) ownership may receive pre-funded warrants with a $0.001 exercise price instead of common stock. Shares outstanding are expected to increase from 4,572,713 to 7,350,491, excluding the underwriters’ 416,667-share over-allotment option.
The company highlights substantial risks, including recurring net losses, substantial doubt about its ability to continue as a going concern, intense competition in AI healthcare, heavy regulatory and cybersecurity demands, and the risk of Nasdaq delisting if it cannot regain and maintain stockholders’ equity compliance.